(Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced positive topline results from its Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback